published meta-analysis   sensitivity analysis   studies

convalescent plasma treatment in infections other than COVID-19 - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathdetailed resultsHung, 2013 1.35 [0.29; 6.26] INSIGHT FLU-IVIG (Davey), 2019 1.18 [0.35; 3.94] IRC005 Study Team, 2019 0.77 [0.21; 2.86] 1.05[0.49; 2.27]Hung, 2013, INSIGHT FLU-IVIG (Davey), 2019, IRC005 Study Team, 201930%482moderatenot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-11-05 19:30 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 92 - treatments: 538,957 - roots T: 290